Literature DB >> 14745018

Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.

Anders Ström1, Johan Hartman, James S Foster, Silke Kietz, Jay Wimalasena, Jan-Ake Gustafsson.   

Abstract

Estrogen receptor (ER) beta counteracts the activity of ERalpha in many systems. In agreement with this, we show in this study that induced expression of ERbeta in the breast cancer cell line T47D reduces 17beta-estradiol-stimulated proliferation when expression of ERbeta mRNA equals that of ERalpha. Induction of ERbeta reduces growth of exponentially proliferating cells with a concomitant decrease in components of the cell cycle associated with proliferation, namely cyclin E, Cdc25A (a key regulator of Cdk2), p45(Skp2) (a key regulator of p27(Kip1) proteolysis), and an increase in the Cdk inhibitor p27(Kip1). We also observed a reduced Cdk2 activity. These findings suggest a possible role for ERbeta in breast cancer and imply that ERbeta-specific ligands may reduce proliferation of ER-positive breast cancer cells through actions on the G(1) phase cell-cycle machinery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745018      PMCID: PMC341775          DOI: 10.1073/pnas.0308319100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Estrogens and cell-cycle regulation in breast cancer.

Authors:  J S Foster; D C Henley; S Ahamed; J Wimalasena
Journal:  Trends Endocrinol Metab       Date:  2001-09       Impact factor: 12.015

2.  Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus.

Authors:  Z Weihua; S Saji; S Mäkinen; G Cheng; E V Jensen; M Warner; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

Authors:  K Paech; P Webb; G G Kuiper; S Nilsson; J Gustafsson; P J Kushner; T S Scanlan
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

4.  Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma.

Authors:  K E Bijwaard; N S Aguilera; Y Monczak; M Trudel; J K Taubenberger; J H Lichy
Journal:  Clin Chem       Date:  2001-02       Impact factor: 8.327

5.  Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.

Authors:  J S Foster; D C Henley; A Bukovsky; P Seth; J Wimalasena
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

6.  Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas.

Authors:  I R Bukholm; G Bukholm; J M Nesland
Journal:  Int J Cancer       Date:  2001-07-15       Impact factor: 7.396

7.  Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer.

Authors:  H K Kim; I A Park; D S Heo; D Y Noh; K J Choe; Y J Bang; N K Kim
Journal:  Eur J Surg Oncol       Date:  2001-08       Impact factor: 4.424

8.  A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells.

Authors:  C Q Lin; J Singh; K Murata; Y Itahana; S Parrinello; S H Liang; C E Gillett; J Campisi; P Y Desprez
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

9.  Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers.

Authors:  K Iwao; Y Miyoshi; C Egawa; N Ikeda; S Noguchi
Journal:  Int J Cancer       Date:  2000-12-01       Impact factor: 7.396

10.  The Hairy and Enhancer of Split homologue-1 (HES-1) mediates the proliferative effect of 17beta-estradiol on breast cancer cell lines.

Authors:  A Ström; N Arai; J Leers; J A Gustafsson
Journal:  Oncogene       Date:  2000-11-30       Impact factor: 9.867

View more
  174 in total

Review 1.  The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

2.  Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter.

Authors:  V Bartella; P Rizza; I Barone; D Zito; F Giordano; C Giordano; S Catalano; L Mauro; D Sisci; M L Panno; S A W Fuqua; S Andò
Journal:  Breast Cancer Res Treat       Date:  2012-05-24       Impact factor: 4.872

3.  Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.

Authors:  Woon-Puay Koh; David Van Den Berg; Aizhen Jin; Renwei Wang; Jian-Min Yuan; Mimi C Yu
Journal:  Breast Cancer Res Treat       Date:  2011-07-21       Impact factor: 4.872

Review 4.  The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk.

Authors:  Valerie A Flores; Hugh S Taylor
Journal:  Endocrinol Metab Clin North Am       Date:  2015-06-23       Impact factor: 4.741

5.  ERβ expression and breast cancer risk prediction for women with atypias.

Authors:  Tina J Hieken; Jodi M Carter; John R Hawse; Tanya L Hoskin; Melanie Bois; Marlene Frost; Lynn C Hartmann; Derek C Radisky; Daniel W Visscher; Amy C Degnim
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

Review 6.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs.

Authors:  Giovanni Nassa; Roberta Tarallo; Giorgio Giurato; Maria Rosaria De Filippo; Maria Ravo; Francesca Rizzo; Claudia Stellato; Concetta Ambrosino; Marc Baumann; Niina Lietzèn; Tuula A Nyman; Alessandro Weisz
Journal:  Mol Cell Proteomics       Date:  2014-02-13       Impact factor: 5.911

8.  Genetic polymorphisms of ESR1, ESR2, CYP17A1, and CYP19A1 and the risk of breast cancer: a case control study from North India.

Authors:  Shilpi Chattopadhyay; Sarah Siddiqui; Md Salman Akhtar; Mohammad Zeeshan Najm; S V S Deo; N K Shukla; Syed Akhtar Husain
Journal:  Tumour Biol       Date:  2014-01-16

9.  E2/ERβ Inhibits PPARα to Regulate Cell-Proliferation and Enhance Apoptosis in Hep3B-Hepatocellular Carcinoma.

Authors:  Shu Nu Chang-Lee; Hsi-Hsien Hsu; Marthandam Asokan Shibu; Tsung-Jung Ho; Chih-Hao Tsai; Ming-Cheng Chen; Chuan-Chou Tu; Vijaya Padma Viswanadha; Wei- Wen Kuo; Chih-Yang Huang
Journal:  Pathol Oncol Res       Date:  2016-10-18       Impact factor: 3.201

10.  Estrogen receptor β, a regulator of androgen receptor signaling in the mouse ventral prostate.

Authors:  Wan-Fu Wu; Laure Maneix; Jose Insunza; Ivan Nalvarte; Per Antonson; Juha Kere; Nancy Yiu-Lin Yu; Virpi Tohonen; Shintaro Katayama; Elisabet Einarsdottir; Kaarel Krjutskov; Yu-Bing Dai; Bo Huang; Wen Su; Margaret Warner; Jan-Åke Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.